Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valentino Gumbilai"'
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Therapeutic approach for NAFLD is limited and there are no approved drugs. Pioglitazone (PGZ), a thiazolidinedione (TZD) that acts via peroxisome proliferator activated receptor gamma (PPARγ) is the only agent that has shown consistent bene
Externí odkaz:
https://doaj.org/article/8d52f04dd21845ac971d00e1cf45c15c
Autor:
Kiminori Hosoda, Megumi Aizawa-Abe, Kazuwa Nakao, Mingming Zhao, Chihiro Ebihara, Tadao Serikawa, Yuji Yamamoto, Ken Ebihara, Tomoji Mashimo, Valentino Gumbilai
Publikováno v:
Diabetes. 65:2954-2965
Agonist-induced activation of peroxisome proliferator–activated receptor-γ (PPARγ) stimulates adipocyte differentiation and insulin sensitivity. Patients with heterozygous PPARγ dominant-negative mutation develop partial lipodystrophy and insuli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93aee33ad0e449cc2f3c59f7b0f4b701
https://doi.org/10.2337/db15-1422
https://doi.org/10.2337/db15-1422
Autor:
Megumi Aizawa-Abe, Sachiko Yamamoto-Kataoka, Mingming Zhao, Daisuke Aotani, Kazuwa Nakao, Miki Nishio, Kiminori Hosoda, Akira Suzuki, Chihiro Ebihara, Takeru Sakai, Yuji Yamamoto, Toru Kusakabe, Valentino Gumbilai, Ken Ebihara
Publikováno v:
Hormone and Metabolic Research. 47:168-175
Nonalcoholic fatty liver disease (NAFLD) is recognized as the hepatic component of the metabolic syndrome. Although NAFLD is a major cause of cirrhosis and cancer of the liver of unknown cause, no established pharmacological treatment for NAFLD has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e46508208b62bbd1c83d3585f98053c
https://doi.org/10.1055/s-0034-1395531
https://doi.org/10.1055/s-0034-1395531
Autor:
Kazuwa Nakao, Michio Noguchi, Junji Fujikura, Takeru Sakai, Mingming Zhao, Chihiro Ebihara, Yuji Yamamoto, Toru Kusakabe, Sachiko Yamamoto-Kataoka, Kiminori Hosoda, Nobuya Inagaki, Daisuke Aotani, Valentino Gumbilai, Megumi Aizawa-Abe, Ken Ebihara
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 307:E712-E719
Leptin may reduce pancreatic lipid deposition, which increases with progression of obesity and can impair β-cell function. The insulinotropic effect of glucagon-like peptide-1 (GLP-1) and the efficacy of GLP-1 receptor agonist are reduced associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a505e0c3154819ef2be31772fce638ed
https://doi.org/10.1152/ajpendo.00272.2014
https://doi.org/10.1152/ajpendo.00272.2014
Autor:
Tsutomu Tomita, Kazuwa Nakao, Toru Kusakabe, Daisuke Aotani, Valentino Gumbilai, Tomoji Mashimo, Ken Ebihara, Takeru Sakai, Sachiko Yamamoto-Kataoka, Tadao Serikawa, Megumi Aizawa-Abe, Mingming Zhao, Chihiro Ebihara, Yuji Yamamoto, Kiminori Hosoda
Publikováno v:
Human molecular genetics. 24(15)
Seipin, encoded by BSCL2 gene, is a protein whose physiological functions remain unclear. Mutations of BSCL2 cause the most-severe form of congenital generalized lipodystrophy (CGL). BSCL2 mRNA is highly expressed in the brain and testis in addition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0c974dcdc2d5ab731b177c39fe0c29f
https://pubmed.ncbi.nlm.nih.gov/25934999
https://pubmed.ncbi.nlm.nih.gov/25934999